Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial-Reference-Cited by-同舟云学术

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

Published:2008-07 Issue:9634 Volume:372 Page:216-223
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Holmes Clive,Boche Delphine,Wilkinson David,Yadegarfar Ghasem,Hopkins Vivienne,Bayer Anthony,Jones Roy W,Bullock Roger,Love Seth,Neal James W,Zotova Elina,Nicoll James AR

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Has the amyloid cascade hypothesis for Alzheimer's disease been proved?;Hardy;Curr Alzheimer Res,2006

2. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse;Schenk;Nature,1999

3. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD;Bayer;Neurology,2005

4. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial;Gilman;Neurology,2005

5. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease;Morgan;Nature,2000

Cited by 1234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dissecting the immune response of CD4⁺ T cells in Alzheimer’s disease;Reviews in the Neurosciences;2024-09-03

2. Mesenchymal stem cell therapy for Alzheimer’s disease: A novel therapeutic approach for neurodegenerative diseases;Neuroscience;2024-09

3. Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going?;Translational Neurodegeneration;2024-08-19

4. Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer’s Disease;Pharmaceutics;2024-07-17

5. Alzheimer's disease pathophysiology in the Retina;Progress in Retinal and Eye Research;2024-07